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Background: Emotional disorders (EDs) are among the most prevalent mental disorders. Existing evidence-based psychological
treatments are not sufficient to reduce the disease burden of mental disorders. It is therefore essential to implement innovative
solutions to achieve a successful dissemination of psychological treatment protocols, and in this regard, the use of information
and communication technologies such as the internet can be very useful. Furthermore, the literature suggests that not everyone
with an ED receives the appropriate treatment. This situation has led to the development of new intervention proposals based on
the transdiagnostic perspective, which attempts to address the underlying processes common to EDs. Most of these transdiagnostic
interventions focus primarily on downregulating negative affectivity (NA), and less attention has been paid to strengths and the
upregulation of positive affectivity, despite its importance for well-being and mental health.
Objective: This study aims to evaluate the efficacy of a transdiagnostic internet-based treatment for EDs in a community sample.
Methods: A 3-armed randomized controlled trial was conducted. A total of 216 participants were randomly assigned to a
transdiagnostic internet-based protocol (TIBP), a TIBP+ positive affect (PA) component, or a waiting list (WL) control group.
The treatment protocol contained core components mainly addressed to downregulate NA (ie, present-focused emotional awareness
and acceptance, cognitive flexibility, behavioral and emotional avoidance patterns, and interoceptive and situational exposure)
as well as a PA regulation component to promote psychological strengths and enhance well-being. Data on depression, anxiety,
quality of life, neuroticism and extraversion, and PA/NA before and after treatment were analyzed. Expectations and opinions
of treatment were also analyzed.
Results: Within-group comparisons indicated significant pre-post reductions in the two experimental conditions. In the TIBP+PA
condition, the effect sizes were large for all primary outcomes (d=1.42, Beck Depression Inventory [BDI-II]; d=0.91, Beck
Anxiety Inventory [BAI]; d=1.27, Positive and Negative Affect Schedule-Positive [PANAS-P]; d=1.26, Positive and Negative
Affect Schedule-Negative [PANAS-N]), whereas the TIBP condition yielded large effect sizes for BDI-II (d=1.19) and PANAS-N
(d=1.28) and medium effect sizes for BAI (d=0.63) and PANAS-P (d=0.69). Between-group comparisons revealed that participants
who received one of the two active treatments scored better at posttreatment than WL participants. Although there were no
statistically significant differences between the two intervention groups on the PA measure, effect sizes were consistently larger
in the TIBP+PA condition than in the standard transdiagnostic protocol.
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Conclusions: Overall, the findings indicate that EDs can be effectively treated with a transdiagnostic intervention via the internet,
as significant improvements in depression, anxiety, and quality of life measures were observed. Regarding PA measures, promising
effects were found, but more research is needed to study the role of PA as a therapeutic component.
Trial Registration: ClinicalTrials.gov NCT02578758; https://clinicaltrials.gov/ct2/show/NCT02578758
International Registered Report Identifier (IRRID): RR2-10.1186/s12888-017-1297-z
(J Med Internet Res 2021;23(2):e21335) doi: 10.2196/21335
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Introduction
Transdiagnostic Treatments for the Common
Psychopathological Processes Underlying Emotional
Disorders
Emotional disorders (EDs) are defined as anxiety and unipolar
mood disorders. These disorders have been grouped based on
their common biological and psychological vulnerabilities [1].
The estimated lifetime prevalence rates for EDs are high (28.8%
for anxiety disorders and 20.8% for mood disorders). In addition,
the co-occurrence of multiple EDs has also been found to be
elevated, with studies showing that more than 40% of people
with one diagnosis also met the diagnostic criteria for a second
disorder over a 12-month period [2].
In recent years, research has demonstrated that evidence-based
psychological treatments (EBTs) are effective in the treatment
of EDs [3]. However, there has been little success in decreasing
the prevalence and incidence of mental illness, and only a small
proportion of people in need actually receive adequate
psychological treatment [4]. In addition, disseminating EBTs
has become a real challenge because of their cost, the duration
of the treatments, and the lack of well-qualified professionals
[5], which can explain why EBTs are underutilized in clinical
practice settings [6].
Recently, transdiagnostic approaches have emerged that address
the common characteristics found in cognitive, behavioral,
emotional, and other dysregulation areas underlying different
EDs, that is, the biological and psychological vulnerabilities
shared by different mental disorders [7,8]. With regard to
transdiagnostic processes, maladaptive emotion regulation
strategies have been suggested as potential explanatory factors
underlying the comorbidity across EDs [9].
In response to transdiagnostic approaches, several
transdiagnostic treatments have been developed to provide
patients with a set of skills geared specifically toward common
vulnerabilities [10]. One example of these treatments is the
Unified Protocol (UP) [7], which was designed to be applicable
across different EDs and represented a significant shift toward
transdiagnostic psychological treatments for EDs [11,12]. The
UP has been tested and results indicate that it is effective in
reducing negative affect (NA) [13], with improvements
maintained at the 18-month follow-up [14]. Furthermore, the
effect of the UP has been shown on the two temperament
dimensions of neuroticism (N)/behavioral inhibition (BI) and
extraversion (E)/behavioral activation (BA) [15].
Mounting evidence demonstrates the efficacy of transdiagnostic
treatments in patients with EDs compared with control groups
[16-19], showing that transdiagnostic treatments are just as
effective as disorder-specific cognitive behavioral therapy (CBT)
[12,20]. The data suggest that a transdiagnostic treatment for
EDs might be more widely effective across a diverse range of
mental disorders, addressing different disorders with a single
protocol [21]. More specifically, a recent meta-analysis showed
that the UP is more effective compared with different control
groups, such as treatment as usual, waitlist, and medication
control groups, in treating anxiety and depressive symptoms
[22].
The Role of Positive Affect in EDs
Regarding the temperamental vulnerabilities, some authors have
identified two essential dimensions of temperament in the
etiology and course of EDs: N/NA and E/positive affect (PA)
[8]. Hence, neuroticism has been identified as a core factor
involved in the development of EDs [23]. In addition, N/NA
and E/PA have been closely related to Gray’s (1987) constructs
of BI and BA, respectively [24-26], and these terms are often
used interchangeably as the most stable measures of
temperament [8,15,26,27]. Thus, people with EDs have higher
levels of N/NA/BI [8], and they experience negative emotions
more intensely and frequently [28] than people who do not have
any ED. In contrast, the dimension of positive emotionality,
E/PA/BA, has also been observed in many disorders, suggesting
that people with an ED show low levels of E/BA [29], which
can predict the onset of depression [30] and increase the severity
of the problem [31]. Despite the importance of PA in health and
well-being, there is limited research on its promotion; therefore,
more research is needed in this area. Furthermore,
notwithstanding the recent upsurge in transdiagnostic treatments
for EDs, most of these protocols have focused on reducing NA.
They have addressed core psychopathological deficits in the
way patients experience and respond to negative emotions [32].
However, less attention has been paid to positive emotions or
promoting PA [33]. In addition to being involved in the
symptomatology of EDs, positive emotionality is considered a
core element of mental health, showing beneficial, generalized
effects on health and functioning [34-37]. Thus, the relationship
between emotion regulation (eg, cognitive reappraisal) and
well-being has also been demonstrated [38]. On the basis of the
literature that highlights the potential importance of positive
emotionality as a treatment component [39-43], it is necessary
to develop and test treatment components focused on
upregulating PA.
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There are many models for delivering interventions in novel
ways that can be scaled up to reach large numbers of people in
need [4]. In this regard, information and communication
technologies (ICTs) play an important role and can facilitate
the availability of EBTs [44]. Specifically, the internet is used
for the assessment and treatment of clinical conditions, and it
has been established as a useful and effective tool for delivering
psychological treatments to treat several psychological disorders
[45], particularly depression and anxiety disorders [46].
Moreover, some meta-analyses have revealed that these
interventions are as efficacious as face-to-face traditional
treatments [47,48].
This Study
The purpose of this study is to test the efficacy of a web-based
psychological treatment protocol for individuals from a
community sample with one or more diagnoses of EDs: major
depressive disorder (MDD), dysthymic disorder (DD),
obsessive-compulsive disorder, and four anxiety disorders: panic
disorder (PD), agoraphobia (AG), generalized anxiety disorder
(GAD), social anxiety disorder (SAD), anxiety disorder not
otherwise specified, and (unipolar) mood disorder not otherwise
specified [49]. Rather than focusing solely on NA, the treatment
protocol includes 2 types of components: one based on classical
perspectives for downregulating NA and the other aimed at
upregulating PA. The protocol can be applied either in its
traditional format (transdiagnostic internet-based protocol,
TIBP) or by including both of these components (TIBP+PA).
Some studies have tested the efficacy of transdiagnostic
interventions in improving PA measures. However, these studies
do not include a specific component to address PA regulation
[13], or they are uncontrolled trials [50-52]. Only one study that
evaluated the efficacy of a new transdiagnostic treatment focuses
on PA, but it is a pilot study rather than a randomized controlled
trial (RCT) [53]. To the best of our knowledge, no published
RCT has tested the efficacy of a transdiagnostic internet-based
treatment for EDs with a specific component to address PA
regulation. Therefore, the aim of this study is to investigate the
effectiveness of this transdiagnostic protocol for EDs, with and
without the specific component to upregulate PA, versus a
wait-list control group. A secondary aim is to test the differential
effect of the specific treatment component designed to
upregulate PA. Finally, we study patients’ acceptance of the
program developed to apply the treatment protocol over the
internet with minimal support by the clinician. We hypothesized
that (1) both self-applied protocol modalities (TIBP and
TIBP+PA) would be more effective than the wait-list control
condition in the treatment of EDs; (2) both interventions would
result in significant improvements in depressive and anxious
symptomatology at posttreatment; (3) the TIBP+PA would
significantly outperform the TIBP group on PA measures; and




This study was a three-armed superiority RCT in which
participants were randomly allocated to 1 of 3 conditions: (1)
TIBP, (2) TIBP+PA, and (3) waiting list (WL) control condition.
For ethical reasons, participants in the control condition were
offered the possibility of receiving the treatment protocol after
spending time on the WL (16 weeks), thus leaving no control
group for the follow-up measurements. Block randomization
was performed to ensure that all primary diagnoses were equally
represented across conditions. The trial was registered at
ClinicalTrial.gov as NCT02578758 on October 16, 2015. The
study was approved by the Ethics Committee of Universitat
Jaume I (Castellón, Spain; May 5, 2016) and was conducted in
compliance with the study protocol, following the Consolidated
Standards of Reporting Trials (CONSORT) statement [54], the
CONSORT-eHealth guidelines [55], and the Standard Protocol
Items: Recommendations for Interventional Trials guidelines
[56,57]. Details of the study protocol have been reported
elsewhere [58]. Different effect sizes found in the literature
based on the transdiagnostic perspective of EDs were considered
to estimate the study power in this study. These calculations
were performed with the software program G*Power 3.1 [59]
and published in the study protocol [58]. This study reports on
pre- to posttreatment data.
Study Population, Recruitment, and Eligibility Criteria
The clinical trial was conducted in a community sample of
individuals diagnosed with one or more of the aforementioned
disorders. Participants were recruited from adult volunteers
interested in participating in the study between June 2015 and
July 2018. Potential participants were attended by phone by the
clinical team members (who had at least a university master’s
degree in general health psychology) to explain the study and
clarify any doubts. People interested in participating signed the
web-based informed consent form and were assessed taking
into account all the inclusion criteria. The inclusion criteria
were as follows: (1) being at least 18 years old; (2) meeting the
Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) diagnostic criteria for EDs; (3) having the
ability to understand and read Spanish; (4) having access to the
internet and an email address; and (5) providing web-based
informed consent. The exclusion criteria were as follows: (1)
having schizophrenia, bipolar disorder, or alcohol and/or
substance dependence disorder; (2) presence of a high risk of
suicide (defined by the Mini-International Neuropsychiatry
Interview [60] as greater than or equal to 10 points); (3) presence
of medical disease/condition that prevents the participant from
carrying out the psychological treatment; and (4) receiving
another psychological treatment during the study. Receiving
pharmacological treatment was not an exclusion criterion, but
any increase and/or change in the medication (in the case of
receiving) during the study period implied the participant’s
exclusion from subsequent analyses. Participants who fulfilled
all the study criteria were randomized to one of the three
experimental conditions by an independent researcher. This
researcher was unaware of the characteristics of the study and
had no clinical involvement in the trial or access to the study
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data. Participants agreed to participate before determining which
treatment they were allocated. All participants were free to
withdraw from the treatment at any time. Access and
participation in the study did not involve payment in any case.
The Transdiagnostic Interventions
The treatment protocol is based on the transdiagnostic
perspective derived from the UP [5,7] and some strategies from
Marsha Linehan’s protocol [61]. Initially, a manualized protocol
was developed and structured in a patient and therapist
handbook. Later, the protocol was adapted to a multimedia web
platform (videos, vignettes, audios, images, etc) to be completely
self-applied via the internet [62] through a PC or a tablet. The
ease of use of the program has been strengthened because it
presents a linear navigation to optimize the treatment structure
and make the treatment easier and more attractive to the
participants.
The program consists of an assessment protocol and a treatment
protocol that includes core components, mainly designed to
downregulate NA (present-focused emotional awareness and
acceptance, cognitive flexibility, behavioral and emotional
avoidance patterns, and interoceptive and situational exposure)
and upregulate PA to promote psychological strengths and
enhance well-being [63]. The protocol content is adapted from
the UP [7] and some of the strategies for emotion regulation
from dialectical behavior therapy [61]. The PA regulation
component is based mainly on BA strategies [64], strategies to
promote pleasant and significant activities linked to values and
life goals, and strategies to enhance personal strengths, positive
feelings, positive cognitions, and positive behavior [63,65].
Furthermore, well-being therapy strategies [66,67] and some
concepts from Fredickson’s Broaden-and-Build Theory [68]
are also included in the program. The PA regulation component
takes place after the NA regulation component. The protocol
also includes traditional therapeutic components of
evidence-based treatment for ED (psychoeducation, motivation
for change, and relapse prevention). All the treatment
components were developed through two self-applied protocol
modalities (TIBP and TIBP+PA) with 12 and 16 modules,
respectively, with the only difference being the inclusion or
absence of the modules that contain the PA-regulation
component. A detailed description of modules that contain the
PA regulation component is presented in Multimedia Appendix
1 [64,66,68-77]. The modules in each intervention protocol are
described briefly elsewhere [58].
The duration of the program could vary among users, and
participants in both treatment conditions had equal access to
the protocol for a maximum period of 18 weeks. The program
sent weekly messages to the patient to remind him/her to
continue to work to benefit from the program. A professional
platform was used to send these messages [78]. The program
also sent automatic emails with reminders to access the modules
when participants had not entered the past 15 days. In addition
to this ICT support, human support was also provided through
weekly phone calls (maximum of 5 min) during the treatment
period to resolve any difficulties or doubts, or to remind them
of the importance of reviewing the treatment contents.
Outcome Measures
The assessment protocol was included at the beginning and end
of the web-based program. A detailed description of the
measures and their aims has been published elsewhere [58].
The measures included in this study are described in Table 1.
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Table 1. Study measures.




BL, Post-Tf0.91.91Severity of depressionBDI-IIe
BL, Post-T0.92.92Severity of anxietyBAIg
BL, Post-TPA=0.91; NA=0.89PAi=.91; NAj=.89Positive and negative affectPANASh
Secondary outcomes
Personality measures
BL, Post-TN=0.82; E=0.84Nl=.81; Em=.84Neuroticism and extraversionNEO FFIk
Quality of life
BL, Post-T0.70.67Health-related quality of lifeEQ-5Dn
Expectation and opinion
BLN/AN/AExpectation of treatmentExpectation of treatment scale
Post-TN/AN/AOpinion of treatmentOpinion of treatment scale
aω: coefficient omega in this study.
bMINI: Mini-International Neuropsychiatric Interview, Version 5.0.0.
cN/A: not applicable.
dBL: baseline.
eBDI-II: Beck Depression Inventory-II.
fPost-T: posttreatment.
gBAI: Beck Anxiety Inventory.
hPANAS: Positive and Negative Affect Schedule.
iPA: positive affect.
jNA: negative affect.





Group differences in participants’sociodemographic and clinical
data at baseline were examined to confirm that they were
comparable after randomization. One-way analysis of variance
for continuous variables and Fisher exact tests of independence
for categorical variables were used. Intention-to-treat (ITT)
using mixed models, with full information maximum likelihood
estimation and without any ad hoc imputations were conducted
to handle missing data due to participant dropout [79]. This
approach uses all available data, does not substitute missing
values with assumed or estimated values, and does not assume
that the last measurement is stable (the last observation carried
forward assumption) [80]. Mixed model analyses are appropriate
for RCTs with multiple time points and pre-to postonly designs
with substantial dropout rates [81]. The pattern of missingness
was investigated to determine its likelihood of being random
rather than systematic (missing not at random, MNAR).
Subsequently, associations between sample characteristics
missingness in the outcome variables were examined (t tests
for continuous variables and Fisher exact tests for categorical
variables). A linear mixed model for each outcome measure
was implemented using the linear mixed-effects models
(MIXED) procedure with one random intercept per subject. An
identity covariance structure was specified to model the
covariance structure of the random intercept. Significant effects
were followed up with pairwise comparisons using the
Bonferroni correction. Effect sizes were calculated for within-
and between-group comparisons using the standardized observed
mean difference proposed by Cohen [82]. To determine the
existence of a reliable change in a patient, the reliable change
index (RCI; Jacobson and Truax’s method) [83] was used. The
RCI values for the primary outcomes (Beck Depression
Inventory, BDI-II; Beck Anxiety Inventory, BAI; Positive and
Negative Affect Schedule-Positive [PANAS-P]; and Positive
and Negative Affect Schedule-Negative [PANAS-N]) were
calculated for the completer sample (participants who provided
data at posttreatment). Fisher exact tests were performed to
evaluate group differences in RCI rates for completers. All
statistical analyses were conducted using IBM SPSS Statistics
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for Windows, version 22, and SAS software, version 9.4, of the
SAS System for Windows.
Results
Participant Flow and Attrition
Out of the 573 people who expressed initial interest in the study,
as the flow diagram shows (Figure 1), only 402 performed the
initial interview. At this stage, 186 participants failed to meet
the inclusion criteria. Finally, 216 patients were included in the
study, and they were randomly allocated to each experimental
condition: TIBP, n=71; TIBP+PA, n=73; WL, n=72. Regarding
pretreatment assessments, 71 participants performed it in the
TIBP, 73 in the TIBP+PA, and 72 in the WL. A similar number
of participants performed the posttreatment assessment from
both intervention conditions (TIBP, n=45; TIBP+PA, n=46).
No significant differences between the three conditions were
found in dropout rates (X22=3.8, P=.14). In the TIBP condition,
of those who started the program (n=71), 26 participants (26/71,
37%) withdrew from the treatment. In the TIBP+PA condition,
a similar pattern was found; of those who started the program
(n=73), 27 participants (27/73, 37%) withdrew from the
treatment. Finally, in the WL control group, data from 55
participants were obtained after they had spent 16 weeks on the
WL (55/72, 76% retention; 17/72, 24% dropout). Overall, of
the 216 participants who started the study, 86 participants
withdrew from the program. As a result, two patterns of
missingness emerged. One of them represented 32% of the
sample (70/216, 32.4%) and the other represented a very low
percentage (16/216, 7.4%). Missingness was not related to the
characteristics listed in Table 2 in any of the three arms of the
RCT (all P>.05 in both patterns). Therefore, patterns of
missingness were not found to be MNAR and the decision to
continue the analysis with the available data was made [84,85].
Figure 1. Flowchart of participants. DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; ED: emotional
disorder; TIBP: Transdiagnostic internet-Based Protocol; PA: positive affect; WL: Waiting List; ITT: intention-to-treat.
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Table 2. Demographic characteristics of participants at pre-assessment (N=216).





33.11 (9.74); 19-5235.82 (13.04);
18-72
Age (years), mean (SD); range
.88X2
2=0.2Sex, n (%)
155 (71.8)53 (74)51 (70)51 (72)Female
61 (28.2)19 (26)22 (30)20 (28)Male
.97N/AeMarital status, n (%)
127 (58.8)42 (58)41 (56)44 (62)Single
75 (34.7)25 (35)27 (37)23 (32)Married or partnered
14 (6.5)5 (7)5 (7)4 (6)Divorced or widowed
.46N/AEducation level, n (%)
9 (4.2)3 (4)5 (7)1 (1)Basic studies
44 (20.4)17 (24)12 (16)15 (21)Medium studies
163 (75.5)52 (72)56 (77)55 (78)Higher studies
.57N/APrincipal diagnosis, n (%)
36 (16.7)16 (22)9 (12)11 (15)MDDf
3 (1.4)2 (3)0 (0)1 (1)DDg
71 (32.9)24 (33)21 (29)26 (37)GADh
16 (7.4)6 (8)6 (8)4 (6)PDi/AGj
9 (4.2)3 (4)4 (6)2 (3)PD
13 (6.0)1 (1)6 (8)6 (9)AG
54 (25.0)16 (22)23 (32)15 (21)SADk
6 (2.8)2 (3)1 (1)3 (4)OCDl
7 (3.2)1 (1)3 (4)3 (4)Anxiety NOSm
1 (0.5)1 (1)0 (0)0 (0)Depression NOS
.17N/ANumber of comorbid disorders, n (%)
81 (37.5)34 (47)19 (26)32 (45)0
92 (42.6)26 (36)36 (49)28 (39)1
57 (62)15 (57)22 (61)18 (64)MDD
6 (7)3 (12)2 (6)1 (4)DD
11 (12)2 (8)7 (19)2 (7)GAD
0 (0.0)0 (0)0 (0)0 (0)PD/AG
1 (1)1 (4)0 (0)0 (0)PD
7 (8)2 (8)2 (6)3 (11)AG
10 (10)3 (11)3 (8)4 (14)SAD
0 (0)0 (0)0 (0)0 (0)OCD
0 (0)0 (0)0 (0)0 (0)Anxiety NOS
0 (0)0 (0)0 (0)0 (0)Depression NOS
27 (12.5)7 (10)12 (16)7 (10)2
7 (26)2 (29)3 (25)2 (29)MDD and GAD
3 (11)1 (14)1 (8)1 (14)MDD and PD/AG
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P valueStatisticdTotal (N=216)WLc (n=72)TIBP+PAb (n=73)TIBPa (n=71)Variable
4 (15)2 (29)1 (8)1 (14)MDD and PD
3 (11)0 (0)2 (17)0 (0)MDD and AG
1 (4)0 (0)0 (0)1 (14)MDD and OCD
1 (4)0 (0)1 (8)0 (0)DD and SAD
4 (15)1 (14)1 (8)2 (29)GAD and SAD
2 (7)0 (0)2 (17)0 (0)GAD and AG
1 (4)1 (14)0 (0)0 (0)PD/AG and SAD
1 (4)0 (0)1 (8)0 (0)SAD and OCD
16 (7.4)5 (7)6 (8)4 (6)3
4 (25)2 (40)1 (17)1 (25)MDD, GAD, and AG
4 (25)2 (40)2 (33)0 (0)MDD, GAD, and SAD
2 (13)0 (0)1 (17)0 (0)MDD, GAD, and OCD
2 (13)0 (0)2 (33)0 (0)MDD, PD, and SAD
1 (6)1 (20)0 (0)0 (0)MDD, PD, and OCD
1 (6)0 (0)0 (0)1 (25)MDD, AG, and SAD
1 (6)0 (0)0 (0)1 (25)MDD, SAD, and OCD
1 (6)0 (0)0 (0)1 (25)GAD, PD/AG, and SAD
aTIBP: transdiagnostic internet-based protocol.
bTIBP+PA: transdiagnostic internet-based protocol+positive affect component.
cWL: waiting list.
dStatistic: Pearson chi-square or Fisher exact test.
eN/A: not applicable.
fMDD: major depressive disorder.
gDD: dysthymic disorder.
hGAD: generalized anxiety disorder.
iPD: panic disorder.
jAG: agoraphobia.
kSAD: social anxiety disorder.
lOCD: obsessive-compulsive disorder.
mNOS: not otherwise specified.
Baseline Data and Participant Characteristics
Details about participants’ sociodemographic characteristics
for each group at pretreatment are presented in Table 2. The
results indicated that there were no significant differences
between the experimental groups before treatment for any of
these variables, indicating that the randomization was successful.
Overall, participants’ mean age was 33.57 years (SD 11.24,
range 18-72), the majority were females (155/216, 71.8%), and
most of them were single (127/216, 58.8%) and had completed
or were pursuing higher studies (163/216, 75.5%; eg,
undergraduate degree studies, graduate studies or university
master’s degrees, or postgraduate studies or doctoral degrees).
Principal and comorbid diagnoses are presented in Table 2.
Most of the participants had GAD (71/216, 32.9%), followed
by SAD (54/216, 25.0%) and MDD (36/216, 16.7%). Regarding
the patterns of comorbidity in the sample, 41.7% (90/216) of
the participants had at least one comorbid diagnosis, with MDD
being the most common comorbid disorder (n=57), followed
by GAD (n=11), SAD (n=10), AG (n=7), DD (n=6), and PD
(n=1).
Regarding the clinical characteristics of the participants in each
experimental condition at pretreatment (Table 3), no statistically
significant differences were found between the groups on any
of the primary and secondary outcomes.
J Med Internet Res 2021 | vol. 23 | iss. 2 | e21335 | p. 8https://www.jmir.org/2021/2/e21335
(page number not for citation purposes)
Díaz-García et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Table 3. Clinical characteristics of participants at pre-assessment.










.141.966 (2213)26.93 (11.76)26.31 (12.43)29.07 (11.33)25.35 (11.33)BDI-IId
.490.719 (2,197)22.23 (12.04)21.87 (12.56)23.58 (11.50)21.14 (12.10)BAIe
.281.277 (2213)19.84 (6.22)19.28 (5.67)19.32 (6.22)20.72 (6.52)PANASf_Positive
.062.807 (2213)30.43 (8.61)28.63 (9.03)31.96 (8.79)30.68 (7.73)PANAS_Negative
Secondary outcomes
Personality measures
.062.853 (2213)32.36 (7.78)31.39 (8.20)34.11 (8.18)31.54 (6.65)NEO FFIg_Neuroticism
.141.991 (2213)20.84 (8.39)21.79 (8.66)19.26 (7.59)21.49 (8.77)NEO FFI_Extraversion
Quality of life
.600.511 (2197)53.75 (18.44)51.91 (17.81)54.78 (19.75)54.60 (17.76)EQ-5Dh
aTIBP: transdiagnostic internet-based protocol.
bTIBP+PA: transdiagnostic internet-based protocol+positive affect component.
cWL: waiting list.
dBDI-II: Beck Depression Inventory-II.
eBAI: Beck Anxiety Inventory.
fPANAS: Positive and Negative Affect Schedule.
gNEO FFI: NEO Five Factor Inventory.
hEQ-5D: EuroQoL-5D questionnaire.
Effectiveness of the Intervention on Primary and
Secondary Outcomes at Pre-Post
Primary Outcomes
Table 4 includes descriptive statistics (ie, means and SD) for
TIBP+PA, TIBP, and WL at pretreatment and posttreatment;
Table 5 includes within-group and between-group effect sizes
and CIs for all the primary outcome measures in the three
experimental groups, based on the ITT sample.
For the three primary outcomes, within-group comparisons
indicated significant pre-post reductions in the two experimental
conditions, with large effect sizes for the BDI-II (d=1.19) and
PANAS-N (d=1.28), and moderate effect sizes for the BAI
(d=0.63) and PANAS-P (d=0.69) in the TIBP condition. In the
TIBP+PA condition, the effect sizes were large for all primary
outcomes (d=1.42, BDI-II; d=0.91, BAI; d=1.27, PANAS-P;
d=1.26, PANAS-N). Between-group comparisons revealed that
participants who received the treatment scored better at
posttreatment than the WL group. Greater reductions were found
in the BDI-II scores in the TIBP condition than in the WL
condition (mean difference −13.61; P<.001; d=1.18; 95% CI
−1.61 to −0.76), as well as between the TIBP+PA condition
and WL (mean difference −14.31; P<.001; d=1.05; 95% CI
−1.46 to −0.63), with large effect sizes. No differences were
found between the two experimental conditions (mean difference
0.70; P=.76; d=0.10; 95% CI −0.51 to −0.31).The results for
BAI scores were similar to the pattern of findings for the BDI:
greater reductions in the TIBP condition (mean difference −8.19;
P=.001; d=0.63; 95% CI −1.07 to −0.20) and TIBP+PA
condition (mean difference −9.28; P<.001; d=0.68; 95% CI
−1.10 to −0.26), compared with WL, with medium effect sizes,
and no differences between the two experimental conditions
(mean difference 1.09; P=.65; d=0.05; 95% CI −0.39 to 0.49).
Finally, patients in the TIBP condition experienced a large
increase in PA (PANAS-P) compared with WL (mean difference
5.42; P<.001; d=0.74; 95% CI 0.33 to 1.15) with moderate effect
sizes and greater reductions in NA (PANAS-N; mean difference
−8.34; P<.001; d=0.99; 95% CI −1.41 to −0.57) compared with
WL with large effect sizes. Participants in the TIBP+PA
condition experienced the same pattern as the participants in
the TIBP condition but achieving large effect sizes for both
higher PA (mean difference 7.86; P<.001; d=0.90; 95% CI 0.49
to 1.31) and lower NA (mean difference −8.32; P<.001; d=0.91;
95% CI −1.32 to −0.50) than participants in the WL condition.
No differences were found between the two experimental
conditions on PA (mean difference −2.44; P=.08; d=0.25; 95%
CI −0.66 to 0.17) or NA (mean difference −0.02; P=.99; d=0.01;
95% CI −0.42 to 0.40).
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Table 4. Descriptive statistics for TIBP+PA, TIBP, and WL at pretreatment and posttreatment for primary outcomes, personality measures, and quality
of life measures.
WLc (n=55), mean (SD)TIBPb (n=45), mean (SD)TIBP+PAa (n=46), mean (SD)Measures
Post-TPre-TPost-TPre-TPost-TePre-Td
Primary outcomes
26.09 (13.99)26.31 (12.42)11.76 (9.02)25.35 (11.33)12.78 (10.76)29.07 (11.33)BDI-IIf
21.67 (14.41)21.87 (12.56)13.46 (10.26)21.14 (12.10)12.97 (10.33)23.58 (11.50)BAIg
19.86 (7.27)19.28 (5.68)25.24 (7.10)20.72 (6.52)27.28 (9.21)19.32 (6.22)Positive Affect subscale of the Positive and
Negative Affect Schedule




31.71 (8.56)31.39 (8.20)26.64 (7.83)31.54 (6.65)27.67 (8.37)34.11 (8.18)Neuroticism subscale of the NEO FFIh
19.84 (10.02)21.79 (8.66)24.13 (8.41)21.49 (8.77)24.22 (7.64)19.26 (7.59)Extraversion subscale of the NEO FFI
Quality of life
52.55 (18.96)51.91 (17.81)64.05 (18.78)54.60 (17.76)68.81 (18.37)54.78 (19.75)EuroQoL-5D-3L questionnaire
aTIBP+PA: transdiagnostic internet-based protocol + positive affect component.




fBDI-II: Beck Depression Inventory-II.
gBAI: Beck Anxiety Inventory.
hNEO FFI: NEO Five Factor Inventory.
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aTIBP+PA: transdiagnostic internet-based protocol+positive affect component.
bTIBP: transdiagnostic internet-based protocol.
cWL: waiting list.
dPost-T: posttreatment.
eBDI-II: Beck Depression Inventory-II.
fBAI: Beck Anxiety Inventory.
gNEO FFI: NEO Five Factor Inventory.
Secondary Outcomes
Table 4 includes descriptive statistics (ie, mean and SD) for
TIBP+PA, TIBP, and WL at pretreatment and posttreatment,
and Table 5 includes within-group and between-group effect
sizes and CIs for secondary outcomes related to personality and
quality of life measures in the three experimental groups based
on the ITT sample.
Regarding personality measures, within-group comparisons
indicated a significant pre-to-post reduction in neuroticism in
the two experimental conditions, with moderate effect sizes in
NEO Five Factor Inventory (NEO FFI)-Neuroticism (d=0.73,
TIBP; d=0.78, TIBP+PA), and a significant pre-to-post increase
in extraversion in the two experimental conditions, with a small
effect size in the TIBP condition (d=0.30) and a moderate effect
size in the TIBP+PA condition (d=0.65). In the WL control
group, significant changes with small effect sizes were also
found on NEO FFI-Extraversion (d=0.22). Between-group
comparisons revealed that participants who received the
treatment scored better at posttreatment on NEO
FFI-Neuroticism in both intervention groups compared with
the WL group, with moderate effect sizes (d=0.61, TIBP;
d=0.47, TIBP+PA). NEO FFI-Extraversion showed better scores
with small effect sizes in both intervention conditions (d=0.46,
TIBP; d=0.48, TIBP+PA) than WL. No statistically significant
differences were found between the two experimental conditions
for the personality measures.
Finally, quality of life measures (ie, EuroQoL-5D Questionnaire;
EQ-5D) showed a significant time effect (F1,152.98=32.98;
P<.001). Both intervention groups experienced significant
improvements in quality of life posttreatment, and this
improvement was not found in the WL control group.
Within-group comparisons indicated moderate effect sizes in
the TIBP condition (d=0.53), moderate effect sizes in the
TIBP+PA condition (d=0.70), and nonsignificant changes in
the WL control group. Between-group comparisons revealed
that participants who received the treatment (with or without
the specific component to upregulate PA) scored higher on
quality of life at posttreatment, compared with the WL, with
moderate effect sizes in the TIBP condition (d=0.60) and large
effect sizes in the TIBP+PA condition (d=0.86; Table 4 for
details). The differences between the two treatment groups were
not statistically significant.
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Table 6 lists the results for the two interventions groups. Items
for expectations and satisfaction were rated from 0 (strongly
disagree) to 10 (strongly agree), covering how logical the
treatment seemed, to what extent it could satisfy the patient,
whether it could be used to treat other psychological problems,
and its usefulness for the patient’s specific problem. Before the
treatment, all the scores were high. The analysis revealed
statistically significant differences between the two conditions
on expectations about the treatment: before treatment,
participants in the TIBP+PA condition considered the treatment
more logical (F1,89=4.49; P=.03), more satisfactory (F1,89=6.29;
P=.01), more recommendable to others (F1,89=6.15; P=.01), and
more useful for other psychological problems (F1,89=7.38;
P=.008) than the TIBP participants did. In addition, at
posttreatment, participants’ satisfaction scores were also high.
The analysis revealed statistically significant differences
between the two conditions on satisfaction: after treatment,
participants in the TIBP+PA condition considered the treatment
more satisfactory (F1,89=4.10; P=.04), recommendable to others
(F1,89=6.79; P=.01), more useful for other psychological
problems (F1,89=5.13; P=.02), and more useful for the patient
(F1,89=5.91; P=.01) than participants in the TIBP condition did.
Table 6. Means and SDs for expectations and satisfaction.
SatisfactionExpectationsStatements
Mean (SD)nMean (SD)n
How logical do you think this treatment is?
8.21 (1.67)918.21 (1.55)91Total sample
8.07 (1.68)457.87 (1.71)45TIBPa
8.35 (1.66)468.54 (1.31)46TIBP+PAb
How satisfied are you with the treatment received?
7.63 (2.02)918.21 (1.75)91Total sample
7.20 (2.04)457.76 (1.86)45TIBP
8.04 (1.93)468.65 (1.54)46TIBP+PA
To what extent do you feel confident about recommending this treatment to a friend who has the same problems?
8.01 (2.12)918.36 (1.77)91Total sample
7.44 (2.32)457.91 (1.95)45TIBP
8.57 (1.75)468.80 (1.45)46TIBP+PA
Do you think this treatment could be useful for treating other psychological disorders?
7.88 (1.76)918.03 (1.72)91Total sample
7.47 (1.89)457.56 (1.79)45TIBP
8.28 (1.53)468.50 (1.52)46TIBP+PA
To what extent do you think the treatment was helpful to you?
7.30 (2.07)917.44 (1.93)91Total sample
6.78 (2.00)457.13 (1.87)45TIBP
7.80 (2.03)467.74 (1.97)46TIBP+PA
aTIBP: transdiagnostic internet-based protocol.
bTIBP+PA: transdiagnostic internet-based protocol+positive affect component.
Reliable and Clinically Significant Change
On the basis of the two criteria proposed by Jacobson and Truax
to estimate clinically meaningful improvement, patients were
classified as recovered, improved, stable, or deteriorated at
posttreatment. The RCI has been expressed graphically to
facilitate a more intuitive interpretation (Figures 2-5). At
posttreatment, statistically significant differences were found
between the three conditions in these percentages for all primary
outcomes: BDI-II (P<.001), BAI (P<.001), PANAS-P (P=.001),
and PANAS-N (P<.001). Overall, participants who received
the transdiagnostic internet-based interventions showed a higher
percentage of recovery compared with WL, which obtained
high percentages of reliable deterioration on all the primary
outcomes. No statistically significant differences were found
between TIBP+PA and TIBP (BDI-II, P=.59; BAI, P=.67;
PANAS-P, P=.59; and PANAS-N, P=.59).
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Figure 2. Percentages of participants recovered, improved, stable, and deteriorated on depression scores (Beck Depression Inventory-II) in transdiagnostic
internet-based protocol+positive affect component (inner circle), transdiagnostic internet-based protocol (middle circle), and waiting list (outer circle).
Figure 3. Percentages of participants recovered, improved, stable, and deteriorated on depression scores (Beck Anxiety Inventory) in transdiagnostic
internet-based protocol+positive affect component (inner circle), transdiagnostic internet-based protocol (middle circle), and waiting list (outer circle).
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Figure 4. Percentages of participants recovered, improved, stable, and deteriorated on depression scores (Positive and Negative Affect Schedule_Positive
subscale) in transdiagnostic internet-based protocol+positive affect component (inner circle), transdiagnostic internet-based protocol (middle circle),
and waiting list (outer circle).
Figure 5. Percentages of participants recovered, improved, stable, and deteriorated on depression scores (Positive and Negative Affect Schedule_Negative
subscale) in transdiagnostic internet-based protocol+positive affect component (inner circle), transdiagnostic internet-based protocol (middle circle),
and waiting list (outer circle).
J Med Internet Res 2021 | vol. 23 | iss. 2 | e21335 | p. 14https://www.jmir.org/2021/2/e21335
(page number not for citation purposes)





The main objective of this study was to test the efficacy of a
transdiagnostic internet-based psychological treatment protocol,
with and without a specific component to upregulate PA, versus
a WL control group, for individuals from a community sample
with one or more ED diagnoses. The results showed that on the
primary outcome measures, there was a significant time effect,
with medium (BAI and PANAS-P) to large effect sizes (BDI-II
and PANAS-N) in the TIBP condition and large effect sizes on
all measures in the TIBP+PA condition. In the WL group, the
effect size was minimal. These results are comparable with
those reported in other transdiagnostic trials in which effect
sizes are larger for depression than for anxiety and higher for
PANAS-P than for PANAS-N [13]. A possible explanation for
the larger effects for depression than for anxiety could be that
the therapeutic techniques more related to the treatment of
anxiety disorders (ie, consequences of emotional avoidance,
emotion-driven behaviors, and interoceptive and situational
exposure) are presented near the end of the treatment protocol
(modules from 8 to 11). Patients are evaluated clinically shortly
after these modules, and consequently, they have less time to
practice them. Likewise, the effects for PA were larger in the
TIBP+PA condition (d=1.27) than in the TIBP condition
(d=0.69). This result is consistent with the fact that this study
includes a specific component to upregulate PA, which places
greater emphasis on positive experiences. One of the aims of
the intervention is to teach patients the adaptive role of both
positive and negative emotions, without the need to suppress
or avoid them. Nevertheless, future studies based on mediational
analyses will allow a better understanding of whether PA and
NA would mediate the impact of treatment on therapy outcomes
(ie, depression and anxiety). As predicted, both protocol
modalities led to significantly greater reductions (relative to the
WL) in depression and anxiety, as well as significant decreases
in NA and increases in PA measures, suggesting that web-based
transdiagnostic treatment was effective in treating EDs.
On the secondary outcomes (NEO FFI and EuroQoL-5D
questionnaire, EQ-5D), the analysis also revealed a significant
change from pre- to posttreatment. The effect sizes were medium
for both variables in both intervention groups (except for
Extraversion, which was smaller in the TIBP condition). In the
WL group, small effect sizes were also found for Extraversion,
showing that participants in this group experienced significantly
lower levels of extraversion after the waiting period.
Between-group comparisons revealed that participants who
received the treatment scored better on the measures at
posttreatment compared with the WL group. These findings
contribute to the study of the malleability of neuroticism
proposed by Barlow [86], who suggests that personality
dimensions may be malleable over time. In this study, some
strategies were proposed to modify PA (extraversion), and
although significant effects were found between the two
intervention groups and the WL group, further research is
needed on this topic to explore the effect of this specific
component on increasing well-being and PA. Along these lines,
Barlow’s team conducted an RCT that evaluated changes in PA
in cognitive-behavioral treatments for anxiety disorders, showing
that PA is a malleable construct and can be influenced by CBT
[87].
The second aim of this study was to assess the effects of the
component designed to upregulate PA, with the hypothesis that
the TIBP+PA condition would significantly outperform the
TIBP condition on the PA measures. This study found no
significant differences between the two treatment conditions
on PA measures. This may be due to the fact that participants
improved throughout the course of the treatment, decreasing
negative symptoms and increasing their PA, even if they had
not seen the last four modules with the specific component to
upregulate PA. Therefore, future studies will be needed to reach
a deeper understanding of the relationship between treatments
that include PA components and changes in PA measures.
Another objective of the study was to study patients’acceptance
of the program developed to apply the treatment protocol over
the internet with minimal support from clinicians. The overall
expectations and satisfaction expressed by the participants in
the two intervention groups were high, and both protocols were
well accepted. However, the analysis revealed higher levels of
expectations and satisfaction in the TIBP+PA condition. This
may be due to the number of modules included in this condition
(16) in comparison with the modules in the TIBP condition (12),
although participants in the intervention groups did not know
the content of those four additional modules. This result may
be influenced by the role of expectations before and during a
web-based psychological intervention, which is consistent with
the literature showing that treatment expectations became more
favorable over time [88]. Regarding the reliable change index,
significant improvements were found in the two treatment
conditions compared with the WL group. Overall, participants
who received the transdiagnostic internet-based interventions
showed higher recovery percentages and less deterioration
compared with the WL group.
This study had a dropout rate of 38.9% (86/216). Some studies
in the literature have indicated dropout rates of approximately
30% in computerized CBT programs [47]. However, this issue
deserves special attention because it depends on how it is
conceptualized. On the one hand, the definition of attrition
differs and can be understood as premature termination [89],
(non)persistence [90], (non)adherence, or the extent to which
an individual is exposed to the content of an intervention [91].
In this study, only participants who completed all the treatment
modules were considered completers, whereas the rest were
treated as dropouts, although in other studies, only participants
who completed a percentage of the modules were considered
completers [92,93]. On the other hand, adherence to
internet-based interventions is associated with the type of
guidance, achieving 28% nonadherence when therapist-guided,
and 38% when administrative support is given [94]. This study
combined human and ICT support, reaching a 36.8% (53/144)
dropout rate in the treatment conditions; therefore, these results
are not far from those found in the existing literature on
internet-based interventions. However, further research on
attrition is needed to better design internet-based treatments and
increase retention. The existing literature has indicated an
important relationship between the support provided to the
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participants and adherence to the program. Indeed, this aspect
has great relevance in the literature on internet-based
interventions [95,96]. Therefore, if this type of intervention is
carried out on a large scale in the community, as in this study,
a fundamental factor to consider is the type and amount of
support to provide, which would be consistent with the study
of the balance between the benefits and resources involved in
providing human support in internet-based interventions.
Technologies play a central role in this aspect because part of
the support can be provided automatically through technological
devices. In an attempt to understand this issue, our research
group conducted a qualitative study to determine why patients
dropped out of the web-based transdiagnostic program for EDs
(TIBP) [97], with the results emphasizing the lack of
individualization of the treatment or the lack of support (ie, the
lack of affective and personal contact with the therapist). In this
regard, future studies should develop personalized treatments
to address patients’ specific needs and increase adherence rates.
There are some useful strategies for personalizing treatments,
such as selecting certain treatment components to better fit the
patient’s symptoms or lowering the number of sessions required
to successfully treat an individual’s symptoms. One strategy
implies personalizing the treatment to a specific presentation,
that is, by selecting the treatment components that best fit the
specific set of symptoms or weaknesses shown by each patient
[10], thereby lowering the number of sessions required to
successfully treat an individual’s symptoms. Another example
is the study by Carl et al [98]. In this study, the authors presented
a module for the regulation of PA that can be added to the
treatment once they have completed the UP modules, thus
personalizing the treatment for patients who show deficits in
positive emotions at posttreatment.
This study has several strengths. First, it presents a novel focus
in the field of transdiagnostic treatments. To the best of our
knowledge, this is the first study of a transdiagnostic
internet-based treatment for EDs with a specific component to
upregulate PA. Overall, the findings indicate that EDs can be
effectively treated with a transdiagnostic intervention via the
internet, in addition to improving depression, anxiety, and
quality of life measures. Regarding PA measures, promising
effects were found, but more research is needed to study the
role of positive emotions in the construction of psychological
strengths [99,100] from a transdiagnostic perspective [42,101].
Moreover, this study included a large sample of people from a
community sample, representing a heterogeneous population
with EDs that does not receive primary or specialized care, with
or without the presence of comorbidities. Thus, the
transdiagnostic protocol represents a successful approach to the
treatment of multiple disorders in a parsimonious manner [102].
Participants in the study seemed to be interested in the use of
adaptive emotion regulation strategies, regardless of whether
they were related to their own difficulty, which is the basis of
transdiagnostic proposals. These interventions emphasize the
essential processes underlying different disorders and the use
of core higher-order strategies that eliminate the need for
multiple diagnosis-specific manuals [103]. Moreover, the
internet-based format of this transdiagnostic protocol facilitates
the availability and administration of the program to provide
support to anyone in need.
Limitations
This study also has some limitations. The most important is the
different number of modules in the two protocols (TIBP
condition: 12 modules; TIBP+PA condition: 16 modules). The
TIBP condition had more time between the last module and
postassessment than the TIBP+PA condition. However, the
TIBP+PA condition had more modules. Postassessment took
place at the end of module 12 or 16. These aspects may have
influenced the results. In an attempt to control this, equal time
(ie, a maximum period of 18 weeks from randomization to
posttreatment evaluation) was given to all participants to allow
them to use the program as much as they desired throughout
the whole process. However, future studies should show that
the differential effect of the PA component is not simply because
of the larger number of modules in the protocol. This leads to
the importance of benchmarking based on previous
transdiagnostic internet-based interventions with regard to effect
sizes or the length of these interventions. This study coincides
with previous similar transdiagnostic interventions that also
obtained large effect sizes for depression (g=0.84) and medium
effect sizes for anxiety (g=0.78), with a treatment length ranging
from 6 to 10 sessions [18]. Furthermore, focusing on PA
measures, it is important to mention that this study obtained
larger effect sizes for PA, both for within- and between-
comparisons (TIBP+PA, d=1.27; TIBP+PA vs WL, d=0.90)
than other transdiagnostic interventions [13,14,50-53]. Another
limitation of the study, shared with other transdiagnostic
interventions, is that although they are called transdiagnostic
treatments, they are based on discrete diagnostic categories (ie,
DSM-IV). Future research should study the mechanistically
transdiagnostic principles, that is, the underlying mechanisms
that account for the occurrence of specific symptoms to include
them in both assessments and transdiagnostic interventions.
Some examples of transdiagnostic mechanisms that have been
found to play a fundamental role in EDs are intolerance to
uncertainty [104], rumination [105], perfectionism [106], or
thought suppression [107]. Among these processes, neuroticism
has been strongly associated with both anxiety and depressive
disorders [86,108]. In addition, attrition rates were higher in
both treatment conditions (TIBP: 26/71, 37%; TIBP+PA: 27/73,
37%) than in the WL condition (17/72, 24%). However, attrition
rates of 30% to 35% are commonly observed in internet-based
interventions [47]. Furthermore, although we consider that the
sample of this study is quite representative, future research
should focus on improving the mental health of less reachable
groups such as older people, people with low income or lower
educational level, and/or people residing outside urban areas
(ie, rural populations). Moreover, it would also be important to
collect data on certain demographic variables such as race,
ethnicity, and sexual orientation in future trials. Transdiagnostic
treatments that are socioculturally adapted for such groups could
be a potential solution to effectively reach a larger number of
people in need of psychological help.
Finally, follow-up data were not included in this study because
we are still in the recruiting process, and we wanted to promptly
provide the results because of the importance of the issue. The
long-term effects of this intervention will be presented in further
research.
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In summary, the results show the efficacy of a transdiagnostic
internet-based psychological treatment protocol for individuals
from a community sample with EDs. These findings show that
this web-based transdiagnostic treatment improved the clinical
situation of the participants, providing them with tools and
strategies to face problems and difficulties more effectively.
Future lines of research should carry out dismantling designs
to determine the active components of the protocol, especially
the contribution of the PA modules, and analyze the
effectiveness of web-based treatment in other populations, such
as primary care centers. Furthermore, the existing techniques
and strategies to improve PA require further study to determine
which ones are more effective and should be included as specific
components to upregulate PA in current psychological
interventions. This study includes some specific strategies to
promote psychological strengths and enhance positive mood.
However, it is important for future studies to explore more
deeply the effect of these and other strategies on patients with
EDs to directly build positive resources to counteract NA.
Undoubtedly, future research will have to determine whether it
is beneficial to include these components designed to enhance
PA, which components are necessary for whom, and how they
should be applied.
Furthermore, future research should focus on the possibility of
developing treatment components aimed at altering, modifying,
or varying vulnerability, a key aspect of transdiagnostic
perspectives. This might be possible with strategies for
modifying PA, but there are other fundamental factors that
influence mental health and well-being. For example, a large
body of literature has highlighted the importance of accurate
perceptions of reality in psychological health, such as positive
illusions or positive self-evaluations, perceptions of control or
mastery, and unrealistic optimism [109,110]. In addition, there
is evidence for the relationship between psychological flexibility
and well-being, suggesting that being psychologically flexible
has benefits for executive functioning, default mental states,
and personality dimensions such as neuroticism [111].
Psychological flexibility has been considered a protective factor
in improving physical health, mental health, and well-being
[112]. Hence, there is growing interest in constructs such as
pragmatic prospection, that is, thinking about a future with
desired outcomes and avoiding undesired ones [113] or openness
to the future characterized by PA toward the future [114]. This
body of knowledge opens up the possibility of finding new
strategies to improve the efficiency and effectiveness of future
transdiagnostic treatment protocols for EDs as a way to more
effectively address temperament vulnerabilities, that is, the core
aspects of these disorders.
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BAI: Beck Anxiety Inventory
BDI-II: Beck Depression Inventory, Second Edition
BI: behavioral inhibition
CBT: cognitive behavioral therapy
CONSORT: Consolidated Standards of Reporting Trials
DD: dysthymic disorder
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E: extraversion
EBT: evidence-based psychological treatment
ED: emotional disorder
GAD: generalized anxiety disorder
ICT: information and communication technology
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NA: negative affect or negative affectivity
NEO FFI: NEO Five Factor Inventory
PA: positive affect
PANAS: Positive and Negative Affect Schedule
PD: panic disorder
RCI: reliable change index
RCT: randomized controlled trial
SAD: social anxiety disorder
TIBP: transdiagnostic internet-based protocol
UP: Unified Protocol
WL: waiting list
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